stockrowAtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024.
- Revenue
- +15.0%
- EPS
- +1,583.9%
- Free cash flow
- −0.73%
- Total debt
- −17.3%
Quarter to September 2026, against a year earlier
Follow ATRC
Alert me
AtriCure, Inc. (ATRC) EV/EBITDA
As of 5 November 2026, AtriCure, Inc. (ATRC) trades at a EV/EBITDA of 83.7×. Over the past ten years it has ranged from 0.0× (December 2025) to 169× (January 2026); the current reading is higher than 98% of that period. That is above the Medical Instruments & Supplies industry median of 14.9× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 157× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 20.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 77.3× | 105.53% |
| Jun 2026 | 37.6× | (48.32%) |
| Mar 2026 | 72.8× | (53.67%) |
| Dec 2025 | 157× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PLSE Pulse Biosciences, Inc compare | n/m |
| MMED MiniMed Group, Inc. compare | n/m |
| XRAY DENTSPLY SIRONA Inc. compare | 9.3× |
| NVST Envista Holdings Corporation compare | 10.3× |
| STVN Stevanato Group S.p.A. compare | 11.3× |
| MMSI Merit Medical Systems, Inc. compare | 15.5× |
| ICUI ICU Medical, Inc. compare | 16.0× |
| WRBY Warby Parker Inc. compare | 50.2× |
| ATRC AtriCure, Inc. | 83.7× |
| Medical Instruments & Supplies industry median | 14.9× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on ATRC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement